Cancer Type: DT/Phase 1

For more information about any of the clinical trials listed on this site, call 314-747-7222 or 800-600-3606 toll free or email Patient_Care_Coordination_Center@bjc.org.

Select Basic Search to view clinical trials grouped by category and Advanced Search to be able to further narrow search results.

 

201407100

A PHASE 1B CLINICAL TRIAL TO EVALUATE THE SAFETY AND IMMUNE RESPONSE TO A MAMMAGLOBIN-A DNA VACCINE IN ER+, HER2- BREAST CANCER PATIENTS UNDERGOING NEOADJUVANT ENDOCRINE THERAPY OR CHEMOTHERAPY

201506113

A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients with Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

201710109

A Randomized Phase 1 Trial of Neoantigen DNA Vaccine Alone vs. Neoantigen Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy

201405031

An Open-Label, Phase 2 Basket Study of Neratinib in Patients with Solid Tumors with Somatic Activating HER Mutations

201508140

A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV associated Solid Tumors with Expansion Cohorts in HIV Associated Solid Tumors and a Cohort of HIV-Associated Classical Hodgkin Lymphoma

201509039

Molecular Analysis for Therapy Choice (MATCH)

201703028

Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors

201711014

A Phase 1, Multicenter, Open-label, Multiple Dose-escalation Study of ARX788, Intravenously Administered as a Single Agent in Subjects with Advanced Cancers with HER2 Expression

201803113

A Phase 1/2 Study of Relatlimab (anti-LAG-3 Monoclonal Antibody) Administered in Combination with Both Nivolumab (anti-PD-1 Monoclonal Antibody) and BMS- 986205 (IDO1 inhibitor) or in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

201810055

A Phase Ia/b Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of BTRC4017A Administered Intravenously as a Single Agent and in Combination with Trastuzumab in Patients with Locally Advanced or Metastatic Her2-Expressing Cancers